Background {#s1}
==========

The prescription of psychotropic drugs has increased in the paediatric population all over the world since about 15 years. This increase varies widely, depending on the country and compounds, ranging from 1.5 to 5 times in many European countries and the USA.[@R1] In the paediatric population, this increase is linked to a major expansion of the prescription of second-generation antipsychotics (SGAs). That is explained, in large part, by the lower occurrence of adverse events (AEs) than with first-generation antipsychotic (FGA) treatment.[@R5] In France, whereas SGA prescriptions are increasing and FGA prescriptions are decreasing over the period 2006--2013, antipsychotic (AP) dispensing rates are stable in persons aged 0--25 years.[@R1] In the USA, AP use increased from 2006 to 2010 for adolescents and young adults but not for children aged 12 years or younger.[@R2]

SGAs have been proven to be effective for treating several conditions in children and adolescents.[@R9] As of March 2010, aripiprazole, olanzapine, quetiapine and risperidone are Food and Drug Administration (FDA)-approved medications for bipolar mania in children and adolescents (age 10--17 years; except olanzapine, age 13--17 years) and for adolescent schizophrenia (age 13--17 years). In addition, aripiprazole and risperidone are also FDA-approved medications for behavioural disturbances (irritability and aggression) associated with autism and/or intellectual disabilities in children and adolescents (age 6--17 years).[@R10] However, naturalistic studies underline that SGAs are prescribed for many off-label indications in paediatric patients in several countries.[@R11] In France, only two SGAs have been granted market authorisation: (1) risperidone for severe behavioural disorders in mental retardation and for autistic syndromes from the age of 5 years, and for schizophrenia and psychosis from the age of 18 years; and (2) aripiprazole for schizophrenia from the age of 15 years, and for moderate to severe manic episodes of bipolar I disorder in adolescents aged 13 years or older. Therefore, many prescriptions of AP are off-label and at discretion of the practitioner.[@R14] [@R15]

Importantly, many major AEs in children and adolescents treated with AP have been reported in the literature.[@R6] [@R16] [@R19] SGA compounds have distinct profiles of secondary effects[@R20] [@R21] and at least some compounds (eg, olanzapine) have more AEs in young patients than in adults.[@R22] The most common AEs of SGAs are metabolic (weight gain, obesity, dyslipidemia, hyperglycaemia, diabetes, insulin resistance), cardiac,[@R10] neuromoto (somnolence/sedation, extrapyramidal syndrome, akathisia, dystonia, catatonia) and endocrine (hyperprolactinaemia).[@R23] Several authors expressed concerns about the consequences of SGAs after long-term exposure in this population.[@R20] [@R27] [@R28] Indeed, the paediatric population treated by AP is at high risk of AEs.[@R16] [@R29] Yet, AEs are often poorly monitored. For example, among children, metabolic monitoring is carried out about two times less than in the adult population.[@R30]

The Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in children (CAMESA) published recommendations for monitoring children and adolescents treated with SGA drugs based on a meta-analysis of studies conducted between 1996 and 2010[@R31] [@R32] The American Diabetes Association, American Psychiatric Association, North American Association for the Study of Obesity and the American Association of Clinical Endocrinologists subsequently issued a joint consensus that expanded the FDA screening recommendations to include a monitoring protocol for children and adolescents starting treatment with SGAs.[@R30] However, these recommendations are based on a limited amount of studies. In a recent experts\' panel discussion on unmet needs, experts highlighted the need for more specific research given the numerous issues raised in paediatric psychopharmacology including: "the frequent off-label prescription of medications to children and adolescents based exclusively on data from randomized controlled studies involving adult patients; the frequent lack of age-specific dose, long-term efficacy and tolerability/safety data; \[...\]; the current lack of biomarkers to predict treatment response and severe AEs; the effective dissemination of evidence-based treatments to the general public, to better inform patients and families of the benefits and risks of pharmacological interventions during development".[@R33]

In conclusion, the published data concerning AEs of the AP treatment in the paediatric population are currently insufficient, limiting the development of standardised recommendations, essential to improve the safe use of drugs in child psychiatry. Moreover, a better understanding of AEs of AP in paediatric patients is needed in order to improve the benefit---risk ratio. In addition, more secure prescriptions should help to reduce global healthcare costs of child psychiatry patients.

Methods/design {#s2}
==============

Ethical consideration, funding and registration {#s2a}
-----------------------------------------------

ETAPE was funded and authorised by the French National Agency for Medicines and Health Products Safety (ANSM, number 2012-004546-15). The study protocol was approved by the Local Ethics Committee of the principal investigator (MLM) 'Sud Méditerrané V' (number 12.082). All patients and their parents signed informed consent on enrolment in the study. The ETAPE study has also been registered on ClinicalTrials.gov (number NCT02007928). It started in April 2013 (the Gantt diagram is shown in [figure 1](#BMJOPEN2015011020F1){ref-type="fig"}).

![Gantt diagram of the ETAPE study. ANSM, French National Agency for Medicines and Health Products Safety; ETAPE, Etude de la Tolérance des AntiPsychotique chez l\'Enfant.](bmjopen2015011020f01){#BMJOPEN2015011020F1}

Objectives {#s2b}
----------

The main objective of this study is the evaluation of the incidence of AE related to AP drugs in a French paediatric population with no history of treatment with AP drugs. Secondary objectives are the evaluation of risk factors associated with the occurrence of AEs, persistence of AEs at the end of the study, evaluation of risk factors associated with changing AP drug, evaluation of disorder\' severity, social functioning, therapeutic alliance, quality of life, eating patterns and physical activity.

Trial design {#s2c}
------------

ETAPE is a naturalistic prospective multicentre study.[@R34] [@R35] Patients were recruited over a period of 25 months (from April 2013 to May 2015). A total of 200 patients have been enrolled in 10 University Departments of Child and Adolescent Psychiatry (Children\'s Hospitals of NICE CHU-Lenval, NICE; University Hospital Pitié Salpêtrière, Paris; Nantes University Hospital, Nantes; Lille University Hospital, Lille; Nancy University Hospital, Nancy; Esquirol Hospital, Limoges; Lyon University Hospitals (HCL Lyon, CH Vinatier, St Jean de Dieu); Toulouse University Hospital, Toulouse; Hospital Fondation Vallée, Gentilly; Poitiers University Hospital, Poitiers; Monaco Hospital) ([figure 2](#BMJOPEN2015011020F2){ref-type="fig"}). Both inpatients and outpatients have been included in the study. The follow-up for each patient is 12 months. Thus, the monitoring period will end in May 2016.

![Inclusion per centre. Legend of [figure 2](#BMJOPEN2015011020F2){ref-type="fig"}: Less than 6 inclusions per centre (Fondation Vallée, Gentilly; Nancy University Hospital; Poitiers University Hospital; Monaco Hospital) N=12 (6%).](bmjopen2015011020f02){#BMJOPEN2015011020F2}

Patients have been included up to 28 days after the introduction of AP drug. Assessments are performed at inclusion and at 3, 6, 9 and 12 month follow-up (M3, M6, M9, M12). Results of laboratory assessment and ECG up to 90 days prior to and 28 days after initiation of AP treatment are considered for the inclusion visit. Follow-up visits are scheduled at 3, 6, 9 and 12 months after the introduction of AP drug (± 14 days). Follow-up and clinical assessments are specified in [table 1](#BMJOPEN2015011020TB1){ref-type="table"}. Given the naturalistic design, prescribing decisions will remain free and independent of the study. Practitioners will take all decisions about change or cessation of AP medication according to their usual clinical practice. Each centre will be responsible for the interpretation of all additional examinations performed during the study.

###### 

ETAPE study procedure and evaluation criteria

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                             Selection   Inclusion   M3   M6   M9   M12
  -------------------------------------------------------------------------------------------------------------------------- ----------- ----------- ---- ---- ---- -----
  Inclusion criteria                                                                                                         ×                                      

  Informed consent                                                                                                           ×                                      

  Somatic parameters weight, height, BMI, waist circumference, blood pressure, temperature                                   --          ×           ×    ×    ×    ×

  Tanner stage                                                                                                               --          ×           --   ×    --   ×

  AIMS[@R36]                                                                                                                                                        

  SAS[@R37] [@R38]                                                                                                           --          ×           ×    ×    ×    ×

  BARS[@R39]                                                                                                                                                        

  BFCRS[@R40]                                                                                                                                                       

  Laboratory assessment                                                                                                                                             

  Full blood count, liver enzymes, creatine phosphokinase, glycaemia, cholesterol (total, HDL, LDL), triglycerides, hsCRP,   --          ×           ×    ×    ×    ×

  Prolactin, insulin, HbA1c, HOMA                                                                                            --          ×           ×    ×    --   ×

  Vitamin D                                                                                                                  --          ×           ×    --   --   ×

  Thyroid hormones                                                                                                           --          ×           --   --   --   ×

  ECG, QTc interval                                                                                                          --          ×           --   ×    --   ×

  Semistructured interview\                                                                                                  --          ×           --   --   --   ×
  K-SADS[@R41]\                                                                                                                                                     
  MINI/MINI-kid[@R42]                                                                                                                                               

  Clinician questionnaires\                                                                                                  --          ×           ×    ×    ×    ×
  CGI-S[@R43] [@R44]                                                                                                                                                

  CGAS[@R45] [@R46]                                                                                                          --          ×           --   ×    --   ×

  PAERS[@R47]                                                                                                                --          ×           ×    ×    ×    ×

  Patient Questionnaires                                                                                                                                            

  QEWP[@R48]                                                                                                                 --          ×           ×    ×    ×    ×

  HAQ[@R49] [@R50]                                                                                                           --          --          ×    ×    ×    ×

  SDS[@R51]                                                                                                                  --          ×           ×    ×    ×    ×

  Dennison[@R52]                                                                                                             --          ×           ×    ×    ×    ×
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

AIMS, abnormal involuntary movement scale; BARS, barnes akathisia rating scale; BFCRS, bush francis catatonia rating scale; BMI, body mass index; CGAS: clinical global assessment scale; CGI-S, clinical global impression scale; ECG, electrocardiogram; HAQ, helping alliance questionnaire; HDL, high-density lipoprotein; hs-CRP, high sensitivity C-reactive protein; HbA1c, glycated haemoglobin; HOMA, insulin resistance; K-SADS, SAS, simpson and angus scale; LDL, low-density lipoprotein; MINI, mini international neuropsychiatric interview; PAERS, pediatric adverse event rating scale; QEWP, questionnaire of eating and weight patterns; schedule for affective disorders and schizophrenia for school age children; SDS, sheehan disability scale.

Inclusion criteria {#s2d}
------------------

The study was proposed to AP-naive children and adolescents with a practitioner\'s prescription of AP. Participants accessed the study either by direct access at the study sites or by referral by a general practitioner or specialists prescribing the medication. Inclusion criteria were as follows: Male or female aged from 6 to 18 yearsTreated by AP drug for less than 28 daysNever having received AP treatment before, or having received AP for less than 3 months and discontinued 6 months prior to the studyInformed consent of parents or guardianInformed consent of child aged 12 years and olderConsent of child aged under 12 yearsAffiliation to French social security

Exclusion criteria {#s2e}
------------------

Since our goal was to conduct a naturalistic study of all types of prescriptions of AP, we did not retain frequently used exclusion criteria such as off-label prescription, patients with severe condition (eg, suicidal behaviour; hospitalisation; comorbid organic condition) and patients with intellectual disability. Therefore, the only exclusion criterion was refusal or withdrawal of consent by the patient or his/her parents.

Measures {#s2f}
--------

Quantitative and qualitative measures are assessed during the study (summary in [table 1](#BMJOPEN2015011020TB1){ref-type="table"}): clinical parameters (eg, body weight), laboratory assessment (eg, blood cholesterol), ECG (eg, QTc interval), semistructured interviews to assess main diagnosis at inclusion and after 12 month follow-up (Kiddie-SADS,[@R41] and/or MINI/MINI-Kid[@R42]), several clinical heteroassessments with a specific rating scale (eg, the Modified Bush-Francis Catatonia Rating Scale, BFCRS[@R40] [@R53]), and several self-report questionnaires (eg, Pediatric Adverse Event Rating Scale, PAERS[@R47]).

Data collection process {#s2g}
-----------------------

Each investigator of the different study centres (child psychiatrist, clinical psychologist, physician, paediatrician, cardiologist) is responsible for collecting and entering data on the paper CRF at the time of the visit. Data control for quality and regulation requirement is realised in each every five inclusions centre by the monitoring clinical research assistant. Results will be entered by the clinical research assistants of the NICE study centre in the database. Double-check in order to avoid missing data or filling errors will be carried out before freezing of the database. Data extraction and analysis of the database (Open Clinica V.3.1.3 Community Edition) will be performed by the Department of Clinical Research and Innovation (DRCI) at NICE University Hospital (data and metadata) after freezing.

Statistical analysis {#s2h}
--------------------

Statistical analysis will be conducted by DRCI at NICE University Hospital using SAS Enterprise Guide V.5.1 (Copyright (c) 1999--2006 by SAS Institute Inc, Cary, North Carolina, USA). A descriptive analysis of all the parameters collected at baseline and during follow-up will be performed. For continuous variables (age, weight, body mass index, etc), indicators such as the mean, SD and range values will be calculated. Categorical data will be presented by means of frequency (n, %).

Changes in the parameters and in the distribution of categorical variables from baseline to follow-up points will be tested with univariate analysis using appropriate testing according to the type of variable and distribution with a level of significance for the p value fixed at \<0.05.

In addition, multivariate analysis will be carried out. An intention-to-treat approach will be used; this means that patients who will be lost to follow-up will be censored at the time of the last visit they attended and included in the analysis. Survival analysis techniques will be performed using Cox analysis for binary outcomes and generalised models for continuous variables. Missing data will also be handled by using the Last Observation Carried Forward method.

Outcomes {#s3}
========

The implementation of this national study should help in raising awareness and educating all French practitioners (child psychiatrists, psychiatrists, paediatricians, general physicians) about AEs of AP in young people. The study will also enable better characterisation of the prescription of AP drugs in children and adolescents and evaluate the incidence of AEs related to AP drugs in a French population with no history of taking AP drugs.

The secondary objectives of the ETAPE study are the assessment of risk factors associated with the occurrence of AEs (eg, age at onset of treatment, pubertal status at baseline, age at onset of disorder for which the prescription of an SGA drug was indicated, type of AP treatment, concomitant treatment, Diagnostic and Statistical Manual Fourth Edition (DSM-IV) diagnosis). In addition, these items will help to identify risk factors associated with change of AP treatment. The course of disorder\' severity, social functioning, therapeutic alliance, quality of life, eating patterns and physical activity during follow-up will also be analysed.

The results will serve to: Help practitioners for prescription decisionsReinforce monitoring of AEs related to AP drugsDevelop recommendations for AP prescription and follow-up by adding original data from a naturalistic studyImprove the safety of AP drugs in child and adolescent psychiatry

The results will further help to develop quality standards and monitoring methods for the prescription of AP in order to improve the benefit/risk ratio.

Discussion {#s4}
==========

The results of this study are very important as AEs of antipsychotic treatment are sometimes overlooked in current practice in child psychiatry. In addition, few studies target the antipsychotic-naive paediatric population.

The ETAPE study proposes a methodology enabling an exhaustive search for AE. Early identification and better understanding of AE will help to improve mental healthcare of the paediatric population, and also reduce the costs of the treatment of AE.

Limitations of the study: The paediatric psychiatric population is very difficult to follow up reliably. There is a high risk of loss to follow-up, which is estimated to be at least 20%. The size of the sample could be limited by these factors. The clinical scales used to assess neuromuscular AEs are validated in the adult population, which might be a limitation for analyses in young patients. Secondary analyses may be limited by the number of patients in each subgroup.
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